|
1
|
Antiretroviral therapies in women after single-dose nevirapine exposure.
|
N Engl J Med
|
2010
|
3.14
|
|
2
|
Carotid artery intima-media thickness and HIV infection: traditional risk factors overshadow impact of protease inhibitor exposure.
|
AIDS
|
2005
|
3.07
|
|
3
|
Progression of carotid artery intima-media thickening in HIV-infected and uninfected adults.
|
AIDS
|
2007
|
1.78
|
|
4
|
Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127.
|
Hepatology
|
2006
|
1.32
|
|
5
|
Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
|
AIDS
|
2007
|
1.29
|
|
6
|
Nevirapine- versus lopinavir/ritonavir-based initial therapy for HIV-1 infection among women in Africa: a randomized trial.
|
PLoS Med
|
2012
|
1.15
|
|
7
|
Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir.
|
J Acquir Immune Defic Syndr
|
2009
|
1.11
|
|
8
|
A pilot study to determine the impact on dyslipidemia of adding tenofovir to stable background antiretroviral therapy: ACTG 5206.
|
AIDS
|
2010
|
1.05
|
|
9
|
Effect of concomitantly administered rifampin on the pharmacokinetics and safety of atazanavir administered twice daily.
|
Antimicrob Agents Chemother
|
2007
|
0.98
|
|
10
|
Effect of nandrolone decanoate therapy on weight and lean body mass in HIV-infected women with weight loss: a randomized, double-blind, placebo-controlled, multicenter trial.
|
Arch Intern Med
|
2005
|
0.82
|
|
11
|
Protease inhibitor-based antiretroviral therapy and glucose tolerance in pregnancy: AIDS Clinical Trials Group A5084.
|
Am J Obstet Gynecol
|
2007
|
0.81
|
|
12
|
Pilot study of pioglitazone before HCV retreatment in HIV/HCV genotype 1-infected subjects with insulin resistance and previous nonresponse to peginterferon and ribavirin therapy: A5239.
|
J Acquir Immune Defic Syndr
|
2014
|
0.77
|
|
13
|
The clinical impact of continuing to prescribe antiretroviral therapy in patients with advanced AIDS who manifest no virologic or immunologic benefit.
|
PLoS One
|
2013
|
0.75
|
|
14
|
Pilot study of low-dose interleukin-2, pegylated interferon-alpha 2b, and ribavirin for the treatment of hepatitis C virus infection in patients with HIV infection.
|
J Infect Dis
|
2005
|
0.75
|